AWM Investment Company Inc. Cuts Stock Position in Orthofix Medical Inc. (NASDAQ:OFIX)

AWM Investment Company Inc. lowered its stake in Orthofix Medical Inc. (NASDAQ:OFIX - Free Report) by 19.9% during the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 360,147 shares of the medical device company's stock after selling 89,309 shares during the period. AWM Investment Company Inc. owned 0.94% of Orthofix Medical worth $6,288,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Renaissance Technologies LLC grew its stake in shares of Orthofix Medical by 166.9% in the 4th quarter. Renaissance Technologies LLC now owns 82,190 shares of the medical device company's stock worth $1,435,000 after buying an additional 51,399 shares during the last quarter. Barclays PLC boosted its stake in Orthofix Medical by 38.8% during the 3rd quarter. Barclays PLC now owns 122,472 shares of the medical device company's stock valued at $1,912,000 after purchasing an additional 34,210 shares during the last quarter. Kirr Marbach & Co. LLC IN purchased a new stake in Orthofix Medical during the 4th quarter valued at $532,000. JPMorgan Chase & Co. boosted its stake in Orthofix Medical by 480.7% during the 3rd quarter. JPMorgan Chase & Co. now owns 84,379 shares of the medical device company's stock valued at $1,318,000 after purchasing an additional 69,848 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new stake in Orthofix Medical during the 4th quarter valued at $1,003,000. Hedge funds and other institutional investors own 89.76% of the company's stock.

Insider Activity

In other news, CEO Massimo Calafiore purchased 10,000 shares of the stock in a transaction dated Friday, May 9th. The shares were purchased at an average cost of $12.54 per share, with a total value of $125,400.00. Following the acquisition, the chief executive officer now directly owns 234,603 shares of the company's stock, valued at $2,941,921.62. This represents a 4.45% increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider Jorge Andres Cedron sold 3,816 shares of the stock in a transaction on Wednesday, April 16th. The shares were sold at an average price of $13.31, for a total value of $50,790.96. Following the transaction, the insider now directly owns 42,500 shares in the company, valued at $565,675. The trade was a 8.24% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 8,475 shares of company stock valued at $128,065 in the last ninety days. 1.30% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

OFIX has been the topic of several recent analyst reports. Roth Mkm reiterated a "buy" rating and set a $22.00 target price on shares of Orthofix Medical in a research note on Wednesday, February 26th. Wall Street Zen downgraded Orthofix Medical from a "buy" rating to a "hold" rating in a research note on Wednesday, May 7th. Finally, Canaccord Genuity Group reiterated a "buy" rating and set a $24.00 target price on shares of Orthofix Medical in a research note on Wednesday, February 26th.

Orthofix Medical Stock Performance

Shares of NASDAQ OFIX traded down $0.13 during midday trading on Friday, hitting $11.10. 572,966 shares of the stock traded hands, compared to its average volume of 267,272. The firm has a 50-day moving average of $13.89 and a two-hundred day moving average of $16.59. The firm has a market capitalization of $433.14 million, a P/E ratio of -3.55 and a beta of 0.87. The company has a debt-to-equity ratio of 0.25, a quick ratio of 1.11 and a current ratio of 2.39. Orthofix Medical Inc. has a one year low of $10.50 and a one year high of $20.73.

Orthofix Medical Company Profile

Orthofix Medical Inc operates as a spine and orthopedics company in the United States, Italy, Germany, the United Kingdom, France, Brazil, and internationally. It operates through two segments, Global Spine and Global Orthopedics. The Global Spine segment manufactures and distributes bone growth stimulator devices for enhance of bone fusion, including adjunctive and noninvasive treatment of cervical and lumbar spine, as well as a therapeutic treatment for non-spine; designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and offers biological products, such as fiber-based and particulate demineralized bone matrices, cellular bone allografts, collagen ceramic matrices, and synthetic bone void fillers, and tissue forms, which allow physicians to treat various spinal and orthopedic conditions.